Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
source: pixabay.com

Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases

  According to a recent article in Business Wire, it is estimated that five million people in the United States over the age of sixty-five are coping with Alzheimer’s at…

Continue Reading Patients Receive First Dosing of Experimental Drug Targeting Neurodegenerative Diseases
New Blood Test Improves Alzheimer’s Disease Diagnosis
source: pixabay.com

New Blood Test Improves Alzheimer’s Disease Diagnosis

  A blood test that gives a more accurate diagnosis of Alzheimer’s disease was announced at the July 2020 International Conference of the Alzheimer’s Association. The Association estimates that approximately…

Continue Reading New Blood Test Improves Alzheimer’s Disease Diagnosis
Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
source: pixabay.com

Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets

  As of right now, there are no treatments for Alzheimer's disease, a progressive neurodegenerative disorder. However, that may soon change. A study led by UCLA researchers identified potential drug…

Continue Reading Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
source: pixabay.com

Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease

  According to a recent article in BioSpace, Biogen and Eisai have launched a new preclinical Phase III trial of BAN2401 to treat pre-clinical Alzheimer's disease. The new study follows…

Continue Reading Researchers’ Attention is Shifting to a New Theory About Alzheimer’s Disease
Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
source: pixabay.com

Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward

As reported in Parkinson's News Today, an investigational therapy to treat patients with Alzheimer's disease and Parkinson’s disease has had its Phase 2 trial approved by the central institutional review…

Continue Reading Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
source: pixabay.com

Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease

  Parkinson’s News Today recently published an article containing new information about biomarkers in Alzheimer’s disease that can be linked to the early stages of Parkinson’s disease. Many people with…

Continue Reading Biomarkers in Alzheimer’s Give Researchers a Heads Up to Predict Early Parkinson’s Disease
Caring for Someone with Alzheimer’s Disease During COVID-19
5239640 / Pixabay

Caring for Someone with Alzheimer’s Disease During COVID-19

COVID-19 is difficult for many of us. We are facing an unprecedented time and questions abound. How do we handle our work, our families, our health? If you are a…

Continue Reading Caring for Someone with Alzheimer’s Disease During COVID-19
Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease
Free-Photos / Pixabay

Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease

According to an article in The Asahi Shimbun, Japanese scientists have developed a new vaccine to mitigate neuronal degeneration caused by Alzheimer's disease. The vaccine, delivered nasally, had promising results…

Continue Reading Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease

Gut Bacteria May Soon be Treating a Wide Range of Illnesses

During the past fifteen years there has been ever-increasing interest in scientific research in the role of microbiome in human health. According to a recent article in Forbes India, this…

Continue Reading Gut Bacteria May Soon be Treating a Wide Range of Illnesses
Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification
source: pixabay.com

Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification

  In February 2020, Epigenetics published results of a study reporting that researchers have found an early sign of Alzheimer’s disease in DNA modification (methylation) that had been overlooked. Patients…

Continue Reading Researchers Have Found an Early Sign of Alzheimer’s Disease in DNA Modification

Using Artificial Intelligence to Study Alzheimer’s and Parkinson’s Disease

Identifying biomarkers may be an improved method of classifying Alzheimer’s and Parkinson’s. As outlined in a recent article covered by Parkinson's News Today, both diseases are diagnosed for the most…

Continue Reading Using Artificial Intelligence to Study Alzheimer’s and Parkinson’s Disease
Study: Results from Phases II/III of Clinical Trial of Gantenerumab, a Treatment for Alzheimer’s Disease
source: pixabay.com

Study: Results from Phases II/III of Clinical Trial of Gantenerumab, a Treatment for Alzheimer’s Disease

Roche has recently released the results of the latest phases of their study of gantenerumab, which is a treatment of a rare form of Alzheimer's disease. This form, which is…

Continue Reading Study: Results from Phases II/III of Clinical Trial of Gantenerumab, a Treatment for Alzheimer’s Disease
A New University of Alabama Study Finds That Norepinephrine is the Missing Piece in the Alzheimer’s Puzzle
source: pixabay.com

A New University of Alabama Study Finds That Norepinephrine is the Missing Piece in the Alzheimer’s Puzzle

  It has been evident to scientists for years that Alzheimer’s disease, which affects about five million people in the U.S., is caused by an accumulation of two proteins within…

Continue Reading A New University of Alabama Study Finds That Norepinephrine is the Missing Piece in the Alzheimer’s Puzzle

After 120 Drug Failures, Can this be the Drug to Slow Alzheimer’s Progression?

  Over the years Alzheimer’s patients and their families have seen more than one hundred twenty drugs that were developed for the treatment of Alzheimer's have failed. For a while,…

Continue Reading After 120 Drug Failures, Can this be the Drug to Slow Alzheimer’s Progression?
New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects
source: pixabay.com

New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects

  CNN recently covered a story in the publication Nature about a paper explaining base editing (or prime editing). The researchers who created the technology set forth the process of using base…

Continue Reading New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects

Caregivers of Rare Disease Patients Must Also Care For Themselves

Allostasis Allostasis is a concept coined by Joseph Eyer and Peter Sterling, colleagues at the University of Pennsylvania. In 1981 they published a paper which contested previous theories on the…

Continue Reading Caregivers of Rare Disease Patients Must Also Care For Themselves

Alzheimer’s Disease: A Long Journey and Another Step Forward

  According to a recent article in MedicalXpress, the newest discovery in the search to reduce the risk of AD was through the work of researchers led by Dr. Jaehong Suh,…

Continue Reading Alzheimer’s Disease: A Long Journey and Another Step Forward

Researchers are Working to Repair a Small Step In a Pathway Involved in Neurodegenerative Diseases

It's common knowledge among researchers who study diseases called toxic proteinopathies, that this grou of disorders are the result of misfolded proteins that reside in cells. Certain proteins fail to…

Continue Reading Researchers are Working to Repair a Small Step In a Pathway Involved in Neurodegenerative Diseases

DNA Sequencing Took Years, Now it Takes Hours; As a Result, Researchers Have Discovered The Cause of Four Rare Diseases

Researchers at the University of Tokyo have discovered that one segment of DNA is responsible for four rare diseases. As reported in Science Daily, the university team also believes that…

Continue Reading DNA Sequencing Took Years, Now it Takes Hours; As a Result, Researchers Have Discovered The Cause of Four Rare Diseases

ICYMI: A Good Business Decision vs. The Right Ethical Choice: Conducting Clinical Trials

A recent article written by Craig Klugman debates the ethical obligations pharmaceutical companies have to conduct clinical trials for drugs which have a likely potential to benefit a patient population…

Continue Reading ICYMI: A Good Business Decision vs. The Right Ethical Choice: Conducting Clinical Trials

Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

  Dr. Craig Klugman, a bioethics professor at DePaul University, expresses his opinion in this recent article in Columbia University’s Bioethics.com. Dr. Klugman begins with a discussion of Pfizer’s biological drug,…

Continue Reading Legal and Ethical Questions: What is Pharma’s Obligation to Pursue Development of a Promising but Non-Profitable Drug?

The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

  In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…

Continue Reading The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals
Close Menu